

November 12, 2024

To,  
Listing/Compliance Department  
BSE LTD  
Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai - 400001

To,  
Listing/Compliance Department  
National Stock Exchange of India  
Limited  
"Exchange Plaza", Plot No. C/1,  
G Block Bandra-Kurla Complex,  
Bandra (E), Mumbai - 400051

BSE CODE - 543998

NSE Symbol: VALIANTLAB

Dear Sir/ Madam,

**Subject: Outcome of the Board Meeting pursuant to Regulation 30 of SEBI(Listing Obligations Disclosure Requirements) Regulations, 2015 (Listing Regulations).**

We wish to inform you that Board of Directors at their meeting held today i.e. **Tuesday, November 12, 2024**, inter-alia considered and approved the following:

1. Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024, pursuant to Regulation 33 of Listing Regulations enclosed as **Annexure- A** and extract of the same to be published in the newspapers, pursuant to Regulations 47 of Listing Regulations.

Accordingly, the said Financial Results along with the Audit Report of the Statutory Auditor, namely, Raman S. Shah & Co., Chartered Accountants, is enclosed.

Please note that an extract of aforesaid Audited Standalone and Consolidated Financial Results will be published in the Newspapers, within the stipulated time, pursuant to Regulation 47 of Listing Regulations.

2. Proposal for Increase in Authorised Share Capital of the Company from existing Rs. 45,00,00,000/- (Rupees Forty- Five Crore Only) divided into 4,50,00,000 Equity Shares of Rs. 10 /- each to Rs. 60,00,00,000/- (Rupees Sixty Crore Only) divided into 6,00,00,000 Equity Shares of Rs. 10/- each and thereby consequent alteration to the Memorandum of Association of the Company, subject to approval of shareholders.

**www.valiantlabs.in | CIN : L24299MH2021PLC365904**

**Registered Office:** 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080.  
**T:** 022-49712001 / 49717220 / 49717221 | **E:** investor@valiantlabs.in

3. Appointment of Mr. Ashok Lakhamshi Chheda (DIN: 10776571), as the Non-Executive Independent Director of the Company for a term of 5 (Five) consecutive years with effect from November 12, 2024 upto November 11, 2029 based on the recommendation of Nomination and Remuneration Committee and subject to the approval of Members. The required details pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are annexed herewith as **Annexure-B**.

Further, in terms of BSE Circular bearing Reference No. LIST/COMP/14/2018-19 and NSE Circular bearing Reference No. NSE/CML/2018/24 dated June 20, 2018, we have received confirmation from Mr. Ashok Lakhamshi Chheda, that he is not debarred from accessing capital markets and/ or restrained from holding the office of director by virtue of any order of the SEBI or any other such authority.

4. Resignation of Mr. Velji Karamshi Gogri (DIN: 02714758) as the Non- Executive Independent Director of the Company with immediate effect from November 12, 2024. The required details pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are annexed herewith as **Annexure- B**.
5. Appointment of Ms. Kiran Mudaliar as a Senior Management Personnel, designated as Assistant Manager – Accounts with effect from November 12, 2024. The required details pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are annexed herewith as **Annexure-B**

The Meeting of the Board of Directors Commenced at 11:30 A.M. and concluded at 6:15 P.M.

Please take the same on your records.

Yours Faithfully,  
**For Valiant Laboratories Limited**

**Prajakta Patil**  
**Company Secretary**  
**M. No.- A53370**

**RAMAN S. SHAH & CO**  
**CHARTERED ACCOUNTANTS**

CA Raman S. Shah, B. Com, F.C.A.



**Independent Auditors' Report**

**To Board of Directors of Valiant Laboratories Limited**

**Report on Audit of Standalone Audited Financial Results**

**Opinion**

We have audited the accompanying standalone financial results of **Valiant Laboratories Limited** ("the Company") for quarter ended 30<sup>th</sup> September 2024 and year to date results for the period 1<sup>st</sup> April 2024 to 30<sup>th</sup> September 2024 ("the financial results") attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

1. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
2. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of the net profit / ( Loss) and total other comprehensive income, and other financial information of the Company for quarter ended 30<sup>th</sup> September 2024 and year to date results for the period 1<sup>st</sup> April 2024 to 30<sup>th</sup> September 2024.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Management's Responsibilities for the Standalone Financial Results**

These quarterly and year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net Profit / ( Loss) and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.



Head Office: - A-102, 1st Floor, Inder Darshan Building, Jamli Gali, Borivali(W), Mumbai (W) 400092





This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management and the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to







the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.


- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For **RAMAN S SHAH & CO**  
**CHARTERED ACCOUNTANTS**  
Firm Registration No.: 111919W

  
Raman S Shah  
Proprietor  
Membership No. 033272  
UDIN: 24033272BKCRNF7083



Place: Mumbai  
Date: 12<sup>th</sup> Nov 2024





## **Independent Auditors' Report**

**To Board of Directors of Valiant Laboratories Limited**

**Report on Audit of Consolidated Audited Financial Results**

### **Opinion**

We have audited the accompanying consolidated financial results of **Valiant Laboratories Limited** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred as "the Group") for quarter ended 30<sup>th</sup> September 2024 and year to date results for the period 1<sup>st</sup> April 2024 to 30<sup>th</sup> September 2024 ("the financial results") attached herewith being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

1. include the results of the following subsidiaries:
  - i. Valiant Advanced Sciences Private Limited
2. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
3. give a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS-34") prescribed under section 133 of the Companies Act 2013 read with relevant rules thereunder and other accounting principles generally accepted in India of the consolidated net profit and consolidated total other comprehensive income and other financial information of the Group for quarter ended 30<sup>th</sup> September 2024 and year to date results for the period 1<sup>st</sup> April 2024 to 30<sup>th</sup> September 2024.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.







### **Management's Responsibilities for the Consolidated Financial Results**

These quarterly and year to date consolidated financial results have been prepared on the basis of the interim financial statements. The Holding Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit / ( Loss ) and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also include maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial results, the respective management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective management and the Board of Directors either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditors' Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
- The risk of not detecting a material misstatement resulting from fraud is higher than for one







resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management and the Board of Directors.
  - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- 
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group, to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





**RAMAN S. SHAH & CO**  
**CHARTERED ACCOUNTANTS**

CA Raman S. Shah, B. Com, F.C.A.



We also performed procedures in accordance with the circular issued by SEBI under regulation 33(8) of the listing regulations, as amended, to the extent applicable.

**Other Matters**

The consolidated financial results include the audited financial results of one subsidiary, whose interim financial Results/ financial information reflects total assets of Rs 36,095.75 lakhs as at 30<sup>th</sup> September 2024, and total Income of Rs. 4,653.45 lakhs and total net Loss after tax of (Rs.525.01 Lakhs) for the quarter ended 30<sup>th</sup> September 2024 and for the period 1<sup>st</sup> April 2024 to 30<sup>th</sup> September 2024 respectively, as considered in the consolidated financial results, which have been audited by their respective independent auditors. The independent auditors' reports on interim/annual financial statements/Financial Results/financial information of these entity have been furnished to us and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.

Our conclusion is not modified in respect of this matter.

For RAMAN S SHAH & CO  
CHARTERED ACCOUNTANTS  
Firm Registration No.: 111919W

Raman S Shah  
Proprietor  
Membership No. 033272  
UDIN: 24033272BKCRNG4206  
Place: Mumbai  
Date: 12<sup>th</sup> November 2024







# Valiant Laboratories Limited

ESTD 1980

Valiant Laboratories Limited  
CIN :- U24299MH2021PLC365904  
ANNEXURE I

Statement of Standalone Audited Financial Results for the Quarter and Half year ended 30th Sep, 2024

Rs. In Lakhs (except EPS)

Sr. No.	Particulars	Standalone					
		Quarter Ended			6 Months Ended		Year Ended
		30-Sep 2024 (Audited)	30-June 2024 (Audited)	30-Sep 2023 (Audited)	30-Sep 2024 (Audited)	30-Sep 2023 (Audited)	31-Mar-2024 (Audited)
1	Income						
	Revenue from Operations	2,147.90	1,888.42	5,954.68	4,036.33	11,095.45	18,205.24
	Other Income	193.42	217.38	295.91	410.80	540.36	968.15
	<b>Total Income</b>	<b>2,341.33</b>	<b>2,105.80</b>	<b>6,250.59</b>	<b>4,447.13</b>	<b>11,635.81</b>	<b>19,173.39</b>
2	Expenses						
a)	Cost of Materials consumed	1,667.59	1,967.63	5,538.70	3,635.22	10,085.69	16,938.68
b)	Purchases of stock in Trade	-	-	-	-	-	-
c)	Changes in inventories of Finished Goods, WIP & Stock-In-Trade	391.59	(67.50)	(57.23)	324.09	(373.56)	(113.63)
d)	Employee benefit expenses	118.91	95.94	104.01	214.85	184.56	431.28
e)	Finance Cost	0.61	5.29	1.91	5.89	3.84	7.78
f)	Depreciation and Amortization	50.59	50.44	49.00	101.03	95.17	194.79
g)	Other expenses*	643.90	131.20	507.81	775.10	955.87	1,789.74
	<b>Total Expenses</b>	<b>2,873.19</b>	<b>2,182.99</b>	<b>6,144.20</b>	<b>5,056.18</b>	<b>10,951.57</b>	<b>19,248.64</b>
3	<b>Profit/(Loss) before exceptional item &amp; tax (1- 2)</b>	<b>(531.86)</b>	<b>(77.19)</b>	<b>106.39</b>	<b>(609.05)</b>	<b>684.24</b>	<b>(75.25)</b>
4	Exceptional Items	-	-	-	-	-	-
5	<b>Profit/ (Loss) before tax (3-4)</b>	<b>(531.86)</b>	<b>(77.19)</b>	<b>106.39</b>	<b>(609.05)</b>	<b>684.24</b>	<b>(75.25)</b>
6	Tax expense (Net)						
(a)	Current Year Tax	(8.74)	8.74	49.80	-	193.22	(98.16)
(b)	Deferred Tax	75.17	14.64	(22.75)	89.81	(15.18)	(11.12)
	<b>Total Tax expense (Net)</b>	<b>66.43</b>	<b>23.38</b>	<b>27.05</b>	<b>89.81</b>	<b>178.04</b>	<b>(109.29)</b>
7	<b>Net Profit/ ( Loss) for the period (5-6)</b>	<b>(598.29)</b>	<b>(100.56)</b>	<b>79.34</b>	<b>(698.86)</b>	<b>506.20</b>	<b>34.03</b>
8	Other Comprehensive Income						
	Item that will not to be reclassified to statement of Profit and Loss						
	Remeasurement of defined benefit Liability/ Assets, net of Taxes	-	-	-	-	-	-
	Fair value changes on Investments, net of Taxes	-	-	17.54	-	17.54	17.54
	<b>Total Other Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>17.54</b>	<b>-</b>	<b>17.54</b>	<b>17.54</b>
9	<b>(Total of profit and other comprehensive income for the year) (7+8)</b>	<b>(598.29)</b>	<b>(100.56)</b>	<b>96.88</b>	<b>(698.86)</b>	<b>523.74</b>	<b>51.57</b>
10	Other Equity excluding revaluation reserve						
11	Paid up equity share capital (face value of Rs.10 each)						
	Earning per equity share ( in Rs.) (not annualised)	4,345.00	4,345.00	3,256.00	4,345.00	3,256.00	4,345.00
(a)	Basic	(1.39)	(0.23)	0.24	(1.61)	1.55	0.14
(b)	Diluted	(1.39)	(0.23)	0.24	(1.61)	1.55	0.14

**Notes:**

- The above results for the Quarter and half year ended 30th Sep, 2024 have been reviewed by the Audit Committee in their meeting held on 12th Nov, 2024 and approved by the Board of Directors in their meeting held on 12th Nov, 2024.
- The Company is operating as a single segment company, engaged in manufacturing of chemicals business, and hence there is no separate reportable business segment.
- The aforesaid Audited Financial results will be uploaded on the company's website [www.valiantlabs.in](http://www.valiantlabs.in) and will also be available on the websites of BSE Limited i.e. [www.bseindia.com](http://www.bseindia.com) / NSE Limited i.e. [www.nseindia.com](http://www.nseindia.com)
- Figures for the previous period have been regrouped or rearranged wherever necessary.
- Other Expenses include a one-time loss adjustment in fair value changes on redemption of mutual funds.\*

Place : Mumbai  
Date - 12th Nov, 2024



SS Vora

Mr Santosh Shantilal Vora  
Managing Director  
DIN - 07633923

[www.valiantlabs.in](http://www.valiantlabs.in) | CIN : L24299MH2021PLC365904

Registered Office: 104, Udyog Kshetra, Mulund Goregaon Link Rd, Mulund West, Mumbai 400 080, India.


T: 022-49712001 / 49717220 / 49717221 | E: [marketing@valiantlabs.in](mailto:marketing@valiantlabs.in)





# Valiant Laboratories Limited

ESTD 1980

Valiant Laboratories Limited CIN :- U24299MH2021PLC365904 ANNEXURE I							
Statement of Consolidated Audited Financial Results for the Quarter and Half year ended 30th Sep, 2024							
Rs. In Lakhs (except EPS)							
Sr. No.	Particulars	Consolidated					
		Quarter Ended			6 Months Ended		Year Ended
		30-Sep 2024 (Audited)	30-June 2024 (Audited)	30-Sep 2023 (Audited)	30-Sep 2024 (Audited)	30-Sep 2023 (Audited)	31-Mar-2024 (Audited)
1	Income						
	Revenue from Operations	2,147.90	1,888.42	5,954.68	4,036.33	11,095.45	18,205.72
	Other Income	335.73	281.39	295.91	617.12	540.36	968.15
	<b>Total Income</b>	<b>2,483.64</b>	<b>2,169.81</b>	<b>6,250.59</b>	<b>4,653.45</b>	<b>11,635.81</b>	<b>19,173.87</b>
2	Expenses						
a)	Cost of Materials consumed	1,667.59	1,967.63	5,538.70	3,635.22	10,085.69	16,939.06
b)	Purchases of stock in Trade	-	-	-	-	-	-
c)	Changes in inventories of Finished Goods, WIP & Stock-In-Trade	391.59	(67.50)	(57.23)	324.09	(373.56)	(113.63)
d)	Employee benefit expenses	118.91	95.94	104.01	214.85	184.56	431.27
e)	Finance Cost	0.61	5.29	1.91	5.89	3.84	7.78
f)	Depreciation, Amortization and impairment Expense	51.86	53.46	49.00	105.32	95.17	196.56
g)	Other expenses*	643.90	131.20	507.81	775.10	955.87	1,789.78
	<b>Total Expenses</b>	<b>2,874.46</b>	<b>2,186.01</b>	<b>6,144.20</b>	<b>5,060.47</b>	<b>10,951.57</b>	<b>19,250.82</b>
3	<b>Profit/(Loss) before exceptional item &amp; tax (1- 2)</b>	<b>(390.82)</b>	<b>(16.20)</b>	<b>106.39</b>	<b>(407.02)</b>	<b>684.24</b>	<b>(76.95)</b>
4	Exceptional Items	-	-	-	-	-	-
5	<b>Profit/ (Loss) before tax ( 3-4 )</b>	<b>(390.82)</b>	<b>(16.20)</b>	<b>106.39</b>	<b>(407.02)</b>	<b>684.24</b>	<b>(76.95)</b>
6	Tax expense (Net)						
(a)	Current Year Tax	7.19	19.21	49.80	26.40	193.22	(98.16)
(b)	Deferred Tax	76.06	15.53	(22.75)	91.59	(15.18)	(10.76)
	<b>Total Tax expense (Net)</b>	<b>83.25</b>	<b>34.74</b>	<b>27.05</b>	<b>117.99</b>	<b>178.04</b>	<b>(108.91)</b>
7	<b>Net Profit/ ( Loss) for the period (5-6)</b>	<b>(474.08)</b>	<b>(50.93)</b>	<b>79.34</b>	<b>(525.01)</b>	<b>506.20</b>	<b>31.96</b>
8	Other Comprehensive Income						
	Item that will not to be reclassified to statement of Profit and Loss						
	Remeasurement of defined benefit Liability/ Assets, net of Taxes			17.54		17.54	17.54
	Fair value changes on Investments, net of Taxes						
	<b>Total Other Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>17.54</b>	<b>-</b>	<b>17.54</b>	<b>17.54</b>
9	<b>(Total of profit and other comprehensive income for the year) ( 7+8)</b>	<b>(474.08)</b>	<b>(50.93)</b>	<b>96.88</b>	<b>(525.01)</b>	<b>523.74</b>	<b>49.50</b>
10	Other Equity excluding revaluation reserve						
11	Profit attributable to :						
	Owners of the Company	(474.08)	(50.93)	79.34	(525.01)	506.20	31.96
	Non- Controlling Interest						
	<b>Total Comprehensive Income attributable to :</b>						
	Owners of the Company	(474.08)	(50.93)	96.88	(525.01)	523.74	49.50
	Non- Controlling Interest						
12	Paid up equity share capital (face value of Rs.10 each)						
	Earning per equity share ( in Rs.) (not annualised)						
(a)	Basic	4,345.00	4,345.00	3,256.00	4,345.00	3,256.00	4,345.00
(b)	Diluted	(1.09)	(0.12)	0.24	(0.33)	1.55	0.13
		(1.09)	(0.12)	0.24	(0.33)	1.55	0.13
<b>Notes</b>							
1. Other Expenses include a one-time loss adjustment in fair value changes on redemption of mutual funds.*							
Place : Mumbai Date - 12th Nov, 2024						<b>SS Vora</b> Mr Santosh Shantilal Vora Managing Director DIN - 07633923	

www.valiantlabs.in | CIN : L24299MH2021PLC365904

Registered Office: 104, Udyog Kshetra, Mulund Goregaon Link Rd, Mulund West, Mumbai 400 080, India.


T: 022-49712001 / 49717220 / 49717221 | E: marketing@valiantlabs.in





# Valiant Laboratories Limited

ESTD 1980

Valiant Laboratories Limited CIN :- U24299MH2021PLC365904 ANNEXURE II Standalone and Consolidated Statement of Assets and Liabilities as on 30th Sep, 2024				
Particulars	Rs. In Lakhs			
	Standalone		Consolidated	
	30-Sep-2024 (Audited)	31-Mar-2024 (Audited)	30-Sep-2024 (Audited)	31-Mar-2024 (Audited)
<b>ASSETS</b>				
<b>Non-current assets</b>				
(a) Property, Plant and Equipment	3,022.86	3,097.00	4,863.66	4,941.67
(b) Right of use Assets	54.19	63.72	54.19	63.72
(c) Capital work-in-progress	9.00	21.86	11,331.37	4,264.88
(d) Other Intangible Assets	8.45	-	12.18	-
(e) Goodwill on consolidation	-	-	-	-
(f) Financial Assets				
(i) Investment in Subsidiaries	16,505.80	8,097.33	-	-
(ii) Other Financial Assets	274.43	264.14	370.92	343.95
(g) Other non-current assets	-	1.99	327.79	2,100.11
<b>Total Non-Current Assets</b>	<b>19,874.73</b>	<b>11,546.04</b>	<b>16,960.11</b>	<b>11,714.34</b>
<b>Current assets</b>				
(a) Inventories	516.38	1,001.54	516.38	1,001.54
(b) Financial Assets				
(i) Investments	-	3,761.17	-	3,761.17
(ii) Trade Receivables	2,854.77	4,572.15	2,854.77	4,572.72
(iii) Cash and Cash Equivalents	212.67	222.67	239.78	1,171.82
(iv) Bank Balances Other than Cash & Cash Equivalents	4,155.00	9,449.34	11,657.92	9,449.34
(v) Loans	2.05	3.04	3.05	3.04
(vi) Other	-	-	-	-
(c) Other Current Assets	1,720.02	1,509.09	3,403.74	2,186.76
(d) Current Tax Assets (Net)	452.61	407.81	459.99	408.00
<b>Total Current Assets</b>	<b>9,913.51</b>	<b>20,926.81</b>	<b>19,135.64</b>	<b>22,554.39</b>
<b>TOTAL ASSETS</b>	<b>29,788.24</b>	<b>32,472.85</b>	<b>36,095.75</b>	<b>34,268.73</b>
<b>EQUITY AND LIABILITIES</b>				
<b>EQUITY</b>				
(a) Equity Share Capital	4,345.00	4,345.00	4,345.00	4,345.00
(b) Other Equity	18,644.33	19,343.19	18,816.11	19,341.12
<b>Total Equity</b>	<b>22,989.33</b>	<b>23,688.19</b>	<b>23,161.11</b>	<b>23,686.12</b>
<b>LIABILITIES</b>				
<b>Non-Current Liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	5,940.02	5,940.02	10,458.32	7,466.30
(ii) Lease Liabilities	34.12	42.69	34.12	42.69
(iii) Other financial liabilities	96.14	96.14	96.14	96.14
(b) Provisions	7.97	8.00	7.97	8.00
(c) Deferred Tax Liabilities (net)	151.20	61.40	153.38	61.77
<b>Total non-current liabilities</b>	<b>6,229.45</b>	<b>6,148.26</b>	<b>10,749.93</b>	<b>7,674.91</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	-	-	1,042.68	138.75
(ii) Lease Liabilities	23.10	23.10	23.10	23.10
(iii) Trade Payables				
A) Total Outstanding Dues of Micro enterprises and Small Enterprises; and	12.83	25.07	12.83	25.07
B) Total Outstanding dues of Creditors other than Micro enterprises and small enterprises	414.03	2,451.36	414.49	2,567.62
(iv) Other Financial Liabilities	81.45	114.88	604.64	121.89
(b) Other Current Liabilities	7.99	10.43	28.31	19.70
(c) Provisions	30.05	11.56	32.27	11.56
(d) Current Tax Liabilities (Net)	-	-	26.39	-
<b>Total Current Liabilities</b>	<b>569.44</b>	<b>2,636.40</b>	<b>2,184.70</b>	<b>2,907.69</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>29,788.24</b>	<b>32,472.85</b>	<b>36,095.75</b>	<b>34,268.73</b>
Previous period figures are regrouped / rearranged wherever required.				
<div>Place : Mumbai Date - 12th Nov, 2024</div> <div><div>SS Vora Mr Santosh Shantilal Vora Managing Director DIN - 07633923</div></div>				

www.valiantlabs.in | CIN : L24299MH2021PLC365904

Registered Office: 104, Udyog Kshetra, Mulund Goregaon Link Rd, Mulund West, Mumbai 400 080, India.


T: 022-49712001 / 49717220 / 49717221 | E: marketing@valiantlabs.in





# Valiant Laboratories Limited

ESTD 1980

VALIANT LABORATORIES LIMITED				
CIN :- U24299MH2021PLC365904				
Standalone and Consolidated Cash Flow Statement as on 30th Sep, 2024				
Particulars	Rs. In Lakhs			
	Standalone		Consolidated	
	30-Sep 2024 (Audited)	30-Sep 2023 (Audited)	30-Sep 2024 (Audited)	30-Sep 2023 (Audited)
<b>(A) Cash Flow from Operating Activities</b>				
Net Profit for the period	(609.05)	684.24	(407.02)	684.24
Adjustments For:				
<b>Add:</b>				
Finance Cost	5.89	3.84	5.89	3.84
Depreciation, Amortization and impairment Expense	101.03	95.17	105.32	95.17
Provision for Gratuity	(8.07)	-	(10.29)	-
Provision for Leave Encashment	(1.59)	-	(1.59)	-
Provision for bonus	(8.79)	-	(8.79)	-
Fair value changes of various Financial instruments	325.12	-	325.12	-
Foreign Exchange Gain/ (Loss)	1.60	-	1.60	-
Profit on disposal of asset	(0.48)	-	(0.48)	-
Provision for doubtful debts	13.68	-	13.68	-
Operating Profit Before Working Capital Changes	(180.66)	783.25	23.44	783.25
Adjustments for:				
(Increase)/Decrease in Trade Receivables	1,703.70	1,881.47	1,717.95	1,881.48
(Increase)/Decrease in Inventories	485.16	(1,022.99)	485.16	(1,022.99)
(Increase)/Decrease Loans	0.98	(1,777.43)	(0.02)	3.08
(Increase)/Decrease Other Current Assets	(209.47)	(431.55)	(1,216.98)	(556.82)
Increase/(Decrease) in Financial Assets	(10.29)	-	(26.97)	(218.95)
(Increase)/Decrease Other non-Current Assets	1.99	(195.43)	1,755.79	(733.78)
Increase/(Decrease) in Trade Payable	(2,049.57)	(317.43)	(2,165.37)	(278.63)
Increase/(Decrease) in Lease Liabilities	(8.57)	(7.79)	(8.57)	(7.80)
Increase/(Decrease) in Other Current Liabilities	(2.43)	(4.32)	8.62	(15.75)
Increase/(Decrease) in Financial Liabilities	(33.44)	(38.85)	482.75	(42.76)
<b>Cash Generated from Operations</b>	(302.60)	(1,131.07)	1,055.79	(209.68)
Less:				
Direct Taxes Paid	-	(193.22)	(26.40)	(193.22)
<b>Cash Flow Before Extraordinary item</b>	(302.60)	(1,324.29)	1,029.39	(402.90)
<b>Net Cash From Operating Activities (A)</b>	(302.60)	(1,324.29)	1,029.39	(402.90)
<b>(B) Cash Flow From Investing Activities</b>				
Purchase of property, plant & equipment (including capital advances)	(24.85)	(281.20)	(7,080.38)	(1,278.83)
Sale of property, plant & equipment	1.43	-	1.43	-
Bank Balances not considered as Cash and Cash Equivalents	5,294.34	(218.00)	(2,208.58)	(218.00)
Other Investment	(8,408.47)	1,720.56	-	-
Redemption of investments	3,436.05	-	3,436.05	1,720.56
<b>Net Cash from Investing Activities (B)</b>	298.49	1,221.36	(5,851.48)	223.73
<b>(C) Cash Flow From Financing Activities</b>				
Proceeds / (Repayment) of Short Term Borrowings	-	73.05	3,895.95	73.05
Interest Paid	(5.89)	(3.84)	(5.89)	(3.84)
<b>Net Cash from/(Used) in Financing Activities (C)</b>	(5.89)	69.22	3,890.06	69.21
Net Increase / (Decrease): in Cash and Cash Equivalents (A+B+C)	(10.00)	(33.71)	(932.03)	(109.96)
Opening Balance of Cash and Cash Equivalents	222.67	37.62	1,171.82	126.16
<b>Closing Balance of Cash and Cash Equivalents including Other Bank Balances</b>	<b>212.67</b>	<b>3.92</b>	<b>239.78</b>	<b>16.20</b>
Previous period's figures are regrouped / rearranged wherever required.				
Place : Mumbai Date - 12th Nov, 2024			 <div> <div>SS Vora</div> <div>Mr Santosh Shantilal Vora Managing Director DIN - 07633923</div> </div>	

www.valiantlabs.in | CIN : L24299MH2021PLC365904

Registered Office: 104, Udyog Kshetra, Mulund Goregaon Link Rd, Mulund West, Mumbai 400 080, India.

T: 022-49712001 / 49717220 / 49717221 | E: marketing@valiantlabs.in



**Annexure- B**

**Brief details of Director seeking appointment, as required under Regulation 30 of the SEBI (Listing Obligations Disclosure Requirements), 2015**

Sr. No.	Particulars	Details	Details	Details
1.	<b>Name</b>	Mr. Ashok Chheda	Mr. Velji Gogri	Ms. Kiran Mudaliar
2.	<b>Date of appointment/ resignation</b>	November 12, 2024	November 12, 2024	November 12, 2024
3.	<b>Reason for Change</b>	Appointment of Mr. Ashok Lakhamshi Chheda as Non-Executive Independent Director of the Company for a term of 5 (five) years with effect from November 12, 2024 up to November 11, 2029 based on the recommendation of Nomination and Remuneration Committee and subject to the approval of Members of the Company.	Resignation due to health concern. There are no other material reasons for resignation other than those mentioned in the resignation letter. Copy of Resignation letter is enclosed herewith.	Appointment of Ms. Kiran Mudaliar as a Senior Management Personnel, designated as Assistant Manager - Accounts based on the recommendation of the Nomination and Remuneration Committee.
4.	<b>Brief profile (applicable in case of appointment)</b>	Mr. Ashok Lakhamshi Chheda (DIN: 10776571) is a Chartered Accountant and a Partner of D.L. Gala & Associates, Chartered Accountant Firm. He has vast experience	Not Applicable	Ms. Kiran Mudaliar is an accomplished Chartered Accountant with over four years of comprehensive expertise, specializing in statutory audits, tax audits, and GST audits. She possesses extensive experience

**www.valiantlabs.in | CIN : L24299MH2021PLC365904**

**Registered Office:** 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080.

**T:** 022-49712001 / 49717220 / 49717221 | **E:** investor@valiantlabs.in



		of over 27 years specialising in Direct and Indirect Tax practice and comprehensive experience in Accounting and Audit.		in the preparation of financial statements and filing of income tax and GST returns. Kiran has an exceptional record of meeting objectives with meticulous precision and operational efficiency, paired with a profound commitment to excelling in environments that foster continual professional advancements.
	<b>Disclosure of Relationships between Directors (applicable in case of appointment)</b>	Not Applicable	Not Applicable	Not Applicable

\*\*\*\*\*



# *Velji Karamshi Gogri*

---

Date: November 12, 2024

To,

The Board of Directors  
**VALIANT LABORATORIES LIMITED**  
104, Udyog Kshetra, Mulund Goregoan Link Road  
Mulund West, Mumbai- 400080

Dear Sir,

**SUB: RESIGNATION AS AN INDEPENDENT DIRECTOR.**

I hereby tender my resignation from the position of Non- Executive Independent Director of the Company, due to health concerns. I request the Board to relieve me of my duties with immediate effect from **November 12, 2024**.


I thank all fellow Board members for their unstinted support and co-operation during my tenure.

Further, I request the Company to intimate the regulatory authorities as required to give effect to this resignation.

I kindly request you to accept the same.

Thanking you,

Yours faithfully,



**Velji Karamshi Gogri**  
Director  
DIN: 02714758